DSIP Peptide: A Complete Guide to Delta Sleep-Inducing Peptide (2026)
What DSIP is, how it's studied for sleep and stress, what the human research really shows, and where it stands with the FDA in 2026.
DSIP, or delta sleep-inducing peptide, is a small 9-amino-acid peptide first found in 1974. It acts as a signaling molecule the body makes on its own, and it's studied for sleep quality and the body's stress response.
It can support deeper, slow-wave sleep by raising delta-wave activity on the EEG, and it is thought to steady the stress-hormone axis that drives cortisol. pru doesn't offer DSIP today. It sits on the FDA's July 2026 review list, and pru plans to offer it the right way, with a physician and a licensed pharmacy, if that path opens.
What is DSIP?
DSIP is delta sleep-inducing peptide, a small chain of nine amino acids that the body makes on its own. Swiss researchers first isolated it in 1974 from the brain blood of sleeping rabbits. They named it for one thing they saw: it raised delta-wave activity on the EEG, the slow brain waves tied to deep sleep. Today it's studied for sleep quality and for calming the stress response.
How popular is DSIP?People search for DSIP about 7,000 times a month in the US (2026 search data). If you're reading this, you're ahead of the curve, among the more informed, proactive people researching an up-and-coming sleep peptide before it reaches the mainstream. See the Peptide Popularity Report for the full ranking.
Its amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), and it's a tiny molecule at about 850 daltons. In FDA compounding documents it also goes by the name emideltide. DSIP is best thought of as a signal the body uses, not a sedative that knocks you out.
| Feature | Detail |
|---|---|
| Full name | Delta sleep-inducing peptide (also called emideltide) |
| Type | Naturally occurring peptide, 9 amino acids |
| Discovered | 1974, from rabbit brain blood |
| Studied for | Sleep quality, stress and cortisol response |
| Half-life | Short, roughly 15 to 25 minutes in blood |
| Human evidence | Early, small, and mixed |
| pru status | Not sold today; on the FDA's July 2026 review list |
How does DSIP work?
DSIP is thought to act as a messenger in the brain rather than a knockout agent. Research suggests it nudges the systems that manage sleep timing and stress, instead of forcing sleep like a sedative does. That's why scientists often call it a sleep-promoting substance, not a sleeping pill.
- Sleep signals: it's thought to support slow-wave, or deep, sleep and to help steady the sleep-wake rhythm.
- Stress response: animal and some human data suggest it can blunt the ACTH and cortisol rise that comes with stress.
- Other hormones: studies link it to growth hormone and luteinizing hormone signaling.
- State-dependent: its support is strongest when sleep is already disrupted, working with the body's own sleep signals where they fall short.
The half-life puzzleDSIP clears from the blood in about 15 to 25 minutes, yet researchers report effects that last hours. That gap points to downstream signaling that outlasts the peptide itself: DSIP acts as a trigger for sleep and stress pathways, so it doesn't have to stay in the blood to keep working.
Is DSIP studied for sleep?
Yes, sleep is the reason DSIP was named and the area it's studied most. The pattern in the research is consistent: DSIP does the most where sleep is broken, raising delta-wave activity and supporting the deep, slow-wave stages the brain uses to recover. It works with the body's own sleep architecture rather than sedating it.
In a double-blind study of people with chronic insomnia, DSIP improved sleep efficiency and how quickly people fell asleep. Later lab work continues to map how it acts on the deep-sleep stages. DSIP is studied for sleep quality; it is not a treatment for insomnia or any sleep disorder. For a wider view of this space, see best peptides for sleep.
What does the research on DSIP show?
DSIP has been studied in humans since the 1970s, across sleep EEG, insomnia, and stress-hormone research. It is studied as a signaling peptide for sleep quality and the stress response. Here is what the main human findings show.
| Study focus | What it looked at | What it found |
|---|---|---|
| Chronic insomnia | Double-blind sleep measures | Small, weak gains in sleep efficiency and latency; judged not a major benefit |
| Disturbed sleep | Synthetic DSIP on broken sleep | Modest effects that were stronger when sleep was already impaired |
| Healthy men | Sleep EEG in normal sleepers | Only minor changes to sleep architecture |
| Stress hormones | Cortisol and ACTH response | Signs of a reduced stress-hormone rise; needs larger human trials |
Is DSIP studied for stress and cortisol?
Yes, beyond sleep, DSIP is studied as a stress-limiting signal. Research points to it lowering the cortisol and ACTH surge that follows stress. It acts on the HPA axis, the hormone loop that governs the body's stress response, helping keep that surge in check.
- It's thought to help steady the stress-hormone axis rather than sedate.
- It signals through the HPA axis to temper cortisol release after stress.
- None of this makes DSIP a treatment for anxiety, depression, or any diagnosed condition.
- For calm and mood, oxytocin is the peptide pru offers today; see oxytocin benefits.
How does DSIP compare to other sleep and calm peptides?
DSIP is one of several peptides people ask about for rest and calm. The split is by evidence and availability: some are still research-only, and one, oxytocin, is a live pru product. Here is how the main names line up.
| Peptide | Mainly studied for | pru status |
|---|---|---|
| DSIP | Sleep quality, stress response | Not sold; July 2026 FDA review |
| Epitalon | Sleep-wake rhythm, aging pathways | Not sold; July 2026 FDA review |
| Oxytocin | Mood, calm, bonding | Live at pru |
If you're mapping this whole category, the best peptides for sleep guide and the epitalon for sleep explainer go deeper on each option.
Is DSIP safe, and what are the side effects?
The long-term safety of DSIP use hasn't been established in clinical research. Short human studies reported that it was generally well tolerated, with only mild effects noted. The main safety consideration is source, which the next point covers.
- Reported effects in studies were generally mild.
- There's no long-term human safety record to lean on.
- It has not been studied for use in pregnancy, breastfeeding, or alongside sleep or psychiatric medications.
- Anyone with a diagnosed sleep, mood, or medical condition should work with a clinician before considering any peptide.
Where the real risk sitsToday DSIP is mostly sold research-grade and grey-market, in vials with no prescriber and no licensed pharmacy behind them. That means no one is confirming purity, dose, or fit for you. That gap, not the peptide's name, is the risk worth taking seriously.
How is DSIP dosed in research?
There's no approved dose for DSIP and no proper human dose-finding study. Research protocols commonly cite small amounts given by injection before intended sleep, but these come from small studies and grey-market practice, not from a regulator. pru doesn't provide dosing guidance for peptides it doesn't sell, and no one should self-dose a research-grade vial.
For a fuller breakdown of what the literature reports, see the DSIP dosage explainer. Any real protocol belongs with a licensed physician, not a forum thread.
What is DSIP's FDA status in 2026?
DSIP sits in a review window. On April 15, 2026 the FDA removed 12 peptides, including DSIP (emideltide), semax, and epitalon, from the 503A Category 2 list. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviews 7 of them on July 23 and 24, 2026, with DSIP, semax, and epitalon set for July 24.
One point matters most here: coming off Category 2 is not FDA approval, and it does not yet place DSIP on the authorized list a 503A pharmacy can compound. It moves the peptide from a do-not-compound status into formal review. Until that review lands, the compliant path stays closed, which is exactly why pru doesn't offer DSIP today.
Plain readingRemoved from Category 2 means DSIP is being looked at again, not that it's approved. The July 2026 PCAC meeting is the next real signal on whether a physician-prescribed, pharmacy-compounded path opens.
How pru handles DSIP
pru isn't selling DSIP today, and it's planning for it the right way, pending the July 2026 PCAC review. The pru model is simple: you select the peptide with guidance from clear content, a licensed physician confirms it fits you, and an FDA-regulated 503A pharmacy compounds and fills it.
Peptides are priced at cost, itemized, with no markup, under a membership of about $50 a month. Getting curious about your sleep and stress is a smart, proactive move, and pru's job is to make the informed choice the accessible one, so when a compliant path for DSIP opens, the responsible route is also the easy one.
- Today: for mood, calm, and bonding, oxytocin is live. See it at oxytocin.
- On the roadmap: DSIP, semax, and epitalon, if the FDA review opens a compliant, pharmacy-compounded path.
- Always: a physician confirms fit; pru never asks you to source a research vial on your own.
- See what membership covers and what peptides cost on the pricing page, and browse the cognition, mood and sleep category.
Why this mattersThe difference between a pharmacy-grade, physician-prescribed peptide and a grey-market vial is oversight: who checks the product, the dose, and whether it's right for you. That's the standard pru is building toward for DSIP.
Related reading
Keep exploring peptides for sleep, calm, and focus:
- Best peptides for sleep
- Epitalon for sleep
- DSIP dosage explained
- Peptides for anxiety and mood
- Oxytocin benefits
- Nootropic peptides guide
- Shop the cognition, mood and sleep catalog
Common questions
Sources & further reading
- https://en.wikipedia.org/wiki/Delta-sleep-inducing_peptide
- https://pubmed.ncbi.nlm.nih.gov/1299794/
- https://pubmed.ncbi.nlm.nih.gov/6145137/
- https://pubmed.ncbi.nlm.nih.gov/7028502/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11498945/
- https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
- https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
- https://www.fda.gov/drugs/human-drug-compounding
- joinpru.com/shop/product/oxytocin